Thermo Fisher Scientific Inc., a world leader in serving science, has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, forconsideration of approximately $1.075 billion, consisting of cash and a $50 million seller note.
The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing. The business generated $645 million in revenue in 2025 and was part of Thermo Fisher’s specialty diagnostics segment.
